The epithelial-mesenchymal transition (EMT) is a biologic process, which allows a polarized epithelial cell to transform fibroblastic mesenchymal cell phenotype \[[@r10]\]. EMT is a crucial event during physiological and disease processes, including development, fibrosis and cancer \[[@r10], [@r19], [@r20]\]. Regarding EMT occurring in cancer progression, tumor cells undergone EMT acquire cell motility and invade the surrounding tissues.

EMT is detected by the loss of epithelial markers, such as ZO-1, E-cadherin and cytokeratin, and up-regulation of mesenchymal markers, such as vimentin, N-cadherin and fibronectin \[[@r11]\]. Several studies have been made on the relationship between EMT and malignancy of human cancers by investigating the expressions of these markers. Vora *et al.* reported that loss of cytokeratin and gain of vimentin expression predicted biological aggressiveness including recurrence and metastasis in human breast cancer \[[@r21]\].

Canine mammary gland tumors (CMGTs) are the most common tumors occurring in female dogs \[[@r4]\]. Histopathologically, approximately 50% of CMGTs are diagnosed as malignant \[[@r3], [@r5]\], and a part of such tumors is associated with dismal survival \[[@r13]\]. Several prognostic factors of CMGTs have been identified. Tumor size, lymph node involvement and distant metastasis are major negative prognostic factors in CMGTs. Prognosis in the dogs with malignant CMGT larger than 3 cm in diameter was obviously worse than that in dogs with malignant CMGT smaller than 3 cm in diameter \[[@r12]\]. A retrospective study reported that the median postoperative survival of dogs with and without distant metastasis at the time of surgery was 5 months and 28 months, respectively \[[@r16]\].

Several variables acquired from laboratory bench have been also suggested as important prognostic factors of CMGTs. Immunohistochemical studies suggested that detection of some cell proteins correlated to clinicopathological features described above and was also valuable prognostic factors in CMGTs. It has been reported that loss of epithelial marker E-cadherin was significantly related to invasive growth and metastasis in dogs with CMGTs \[[@r17]\]. Expression of the transcription factor Snail, which inhibits transcription of E-cadherin, significantly correlated with histological type, grade and lymphatic invasion in CMGTs tissues \[[@r9]\]. On the other hand, the expression of mesenchymal markers vimentin was occasionally found on tumor cells in CMGTs biopsy samples \[[@r7]\], although the role of this phenomenon has remained to be elucidated. These results are typical changes observed in EMT. Therefore, EMT is thought to have strong relationship with malignancy, such as recurrence, metastasis and survival in CMGTs. However, there is no report evaluating both epithelial and mesenchymal markers inclusively in epithelial tumor cells in CMGTs tissues.

In this study, to clarify the relationship between EMT-related proteins and clinicopathological features, especially prognosis, we evaluated the protein expressions of both loss of epithelial markers and gain of mesenchymal markers in epithelial tumor cells in CMGTs tissues which we obtained from clinical cases and investigated the relationship with clinicopathological variables of those cases.

MATERIALS AND METHODS {#s1}
=====================

*Case*: This study included a total of 119 tissue samples from 110 female dogs that were diagnosed as CMGT and underwent surgical resection at the Veterinary Medical Center, the University of Tokyo, between April 1996 and December 2009. Tumor tissues were classified into adenoma (n=10), complex adenoma (n=22), benign mixed tumor (n=39), adenocarcinoma (n=42) and complex adenocarcinoma (n=6) according to the International Histological Classification of Tumors of Domestic Animals of the World Health Organization \[[@r14]\]. When the patient had both benign and malignant CMGTs, malignant CMGT tissue was used in the study. The medical records of applicable cases were reviewed, and clinical data including age, breed, body weight, spay history, anamnestic history, other concurrent disease, experience of lumpectomy, the WHO clinical staging at the time of surgery, operation procedure (unilateral or regional mastectomy), chemotherapy and survival time were collected. Tumor size was calculated as the maximum diameter. Regional lymph node involvement was confirmed by cytopathology, and lung metastasis was confirmed by thoracic radiography. Survival time was defined as the days from surgical resection to death.

*Antibody*: The primary antibodies used for epithelial markers were rabbit polyclonal anti-ZO-1 (Santa Cruz Biotechnology, CA, U.S.A.) and mouse monoclonal anti-E-cadherin (BD Transduction Laboratories, Lexington, KY, U.S.A.), and those for mesenchymal markers were mouse monoclonal anti-vimentin (Dako Japan, Kyoto, Japan), mouse monoclonal anti-N-cadherin (Dako Japan) and rabbit polyclonal anti-fibronectin (Dako Japan).

*Immunohistochemistry*: The summary of the procedure is shown in [Table 1](#tbl_001){ref-type="table"}Table 1.Protocol for immunohistochemistryAntigen-retrievalPrimary antibodyDAB^d)^ZO-1121ºC, 5 min in CB^a)^1:100, 4ºC, over-nightRT, 3 minE-cadherin121ºC, 5 min in CB^a)^1:150, 4ºC, over-nightRT, 3 minVimentin121ºC, 5 min in CB^a)^1:50, 37ºC, 1 hrRT, 1 minN-cadherin121ºC, 15 min in TB^b)^1:50, 37ºC, 50 minRT, 50 secFibronectrinRT^c)^, 5 min, in proteinase K1:1,000, 37ºC, 50 minRT, 50 seca) CB, 10 mM citrate buffer, pH6.0, b) TB, 10 mM Tris buffer, pH9.0 with 1 mM EDTA, c) RT, room temperature, d) DAB, 3, 3′-diaminobenzidin/hydrogen peroxide solution.. Briefly, formalin-fixed paraffin-embedded sections were deparaffinized, followed by antigen epitope retrieval using appropriate methods. Endogenous peroxidase was inactivated by 0.3% hydrogen peroxide in methanol for 10 min. Then, they were blocked in 0.1% Tween-20 in PBS (PBS-T) containing 5% normal goat serum and probed with the primary antibody. After incubation, samples were treated with polymer solution containing HRP-conjugated antibody against mouse immunoglobulin for E-cadherin, vimentin and N-cadherin, and rabbit immunoglobulin for ZO-1 and fibronectin, respectively. Visualizations were done with liquid 3, 3′-diaminobenzidine (DAB)/ hydrogen peroxide solution (Dako Japan) and counterstained with hematoxylin. A normal canine skin tissue was used as positive and negative controls for epithelial and mesenchymal markers, except for N-cadherin. For N-cadherin, normal muscle tissue was used as a positive control.

*Evaluation of the EMT markers*: The evaluation of epithelial and mesenchymal markers was done by one researcher in a blind fashion without clinical information. For each sample, 3 fields of ×200 magnification were randomly selected from intra-tumoral area. Only stained epithelial tumor cells other than myoepithelium were counted, and the percentage of weak stained and negative cells was calculated for epithelial markers, and the percentage of positive cells was calculated for mesenchymal markers. Regarding mesenchymal markers, samples with less than 1% positive of expression were defined as negative to avoid the influence of non-specific false positive.

*Statistical analysis*: Statistical analysis was performed using Excel 2010 or Statview-J 5.0 software, and *P* value\<0.05 was considered statistically significant. A chi-square test was used to evaluate the associations between expression of EMT markers and clinicopathological factors. Spearman's rank-correlation coefficient was performed to determine the relationship between two markers. A multiple logistic regression model yielding adjusted odds ratios was used to clarify the availability as prognostic factors. We selected factors showing the association with one-year survival by univariate analysis (*P*\<0.1). Multicollinearity was assessed by variance inflation factor. A variance inflation factor indicates degree of multicollinearity, and values greater than 4 may be a cause of concern.

RESULTS {#s2}
=======

*Clinical features*: The 119 CMGTs tissues (110 dogs) enrolled in this study are summarized in [Table 2](#tbl_002){ref-type="table"}Table 2.Canine mammary gland tumors clinical samples used in this studyTumor typen (%)BenignSimple adenoma10 (8.4)Complex adenoma22 (18.5)Benign mixed tumor39 (32.8)Total71 (59.7)MalignantSimple carcinoma42 (35.3)Complex carcinoma6 (5.0)Total48 (40.3). This study included following breeds; 20 mongrel, 17 Yorkshire terrier, 14 Maltese, 12 toy poodle, 8 Shih Tzu, 5 miniature dachshund, 5 Shetland sheepdog and 38 other breeds.

*Expression of epithelial markers*: Expressions of ZO-1 and E-cadherin were observed on the cell membrane and/or cytoplasm ([Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Representative findings of immunohistochemistry with antibodies against epithelial markers ZO-1 and E-cadherin. (A) Strong expression of ZO-1 was observed in tumor cells. (B) ZO-1 was weakly expressed in tumor cells (arrowheads). (C) E-cadherin was strongly expressed in tumor cells. (D) E-cadherin was weakly expressed in tumor cells (arrows). Occasionally, disappearance of E-cadherin was observed (arrowhead).). The number of samples in which weak or negative expression of ZO-1 was observed was significantly larger in dogs ≥10 years (21 of 68) than in dogs \<10 years (3 of 51). The number of samples in which weak or negative expression of ZO-1 was observed was significantly larger in dogs with malignant CMGT (21 of 48) than in dogs with benign CMGT (3 of 71). The number of samples in which weak or negative expression of E-cadherin was observed was significantly larger in dogs with stages IV and V CMGT (7 of 13) than in dogs with I, II and III grade CMGT (14 of 106). The number of samples in which weak or negative expression of E-cadherin was observed was significantly larger in dogs with malignant CMGT (14 of 48) than in dogs with benign CMGT (7 of 71).

*Expression of mesenchymal markers*: Mesenchymal markers were observed in the cytoplasm ([Fig. 2](#fig_002){ref-type="fig"}Fig. 2.Representative findings of immunohistochemistry with antibodies against mesenchymal markers, vimentin, N-cadherin and fibronectin. (A) Vimentin was negative in tumor cells. (B) Vimentin was clearly expressed in tumor cells (arrowheads). (C) N-cadherin was negative in tumor cells. (D) Positive expression of N-cadherin was observed in tumor cells (arrowheads). (E) Fibronectin was negative in tumor cells. (F) Fibronectin was expressed in tumor cells.). The number of samples in which≥1% positive expression of vimentin was observed was significantly larger in dogs ≥10 years (17 of 68) than in dogs \<10 years (4 of 51). The number of samples in which ≥1% positive expression of vimentin was observed was significantly larger in dogs with malignant CMGT (19 of 48) than in dogs with benign CMGT (2 of 71). The number of samples in which ≥1% positive expression of N-cadherin was observed was significantly larger in dogs with malignant CMGT (10 of 48) than in dogs with benign CMGT (1 of 71). There is no significant relationship between expression of fibronectin and clinicopathological characteristics ([Table 3](#tbl_003){ref-type="table"}Table 3.Correlations between change of epithelial and mesenchymal markers and clinicopathological variablesLoss ofGain ofOverallZO-1E-cadherinVimentinN-cadherinFibronectinAge (year)\<1035442951≥1021161774568*P*0.002^b)^0.090.03^a)^0.890.3Body weight (kg)\<1016141394982≥1087822537*P*0.990.990.610.530.42Ovarian statusspayed64511116intact1817161063103*P*0.130.630.240.980.76Experience of mastectomyfirst14151265588experienced1069519103*P*0.090.990.10.240.9Tumor size (cm)\<398723660≥3871422537*P*0.230.320.140.0540.62Clinical stageI--III201417864106IV and V47431013*P*0.520.001^b)^0.350.190.39Histopathological typebenign37214671malignant211419102848*P*\<0.001^b)^0.014^a)^\<0.001^b)^0.001^b)^0.48a) *P*\<0.05, b) *P*\<0.01.).

*The correlation between each marker*: To evaluate whether expression levels of used markers relate to each other, Spearman's rank-correlation coefficient between two markers was calculated. There is no strong positive correlation between used markers ([Table 4](#tbl_004){ref-type="table"}Table 4.Correlations between epithelial and mesenchymal markersSpearman's rank-correlation coefficient (ρ)Loss ofGain ofZO-1E-cadherinVimentinN-cadherinFibronectinLoss of ZO-1--0.34^b)^0.34^b)^0.21^a)^−0.03Loss of E-cadherin--0.150.110.07Gain of Vimentin--0.19^a)^0.20^a)^Gain of N-cadherin--−0.26^b)^Gain of Fibronectin--a) *P*\<0.05, b) *P*\<0.01.).

*The relationship between change of EMT markers and one-year survival*: Thirteen dogs died of CMGT within a year after surgery. Although necropsy was not allowed in any cases, we judged these dogs died of CMGT because they showed progression of distant metastasis and associated clinical signs. On the other hand, 25 dogs with malignant CMGTs survived more than one year. [Table 5](#tbl_005){ref-type="table"}Table 5.Relationship between various parameters and one-year survivalVariables*P*OR^a)^ (95% CI^b)^)Age0.272.6 (0.5--14.5)Body weight0.691.3 (0.3--5.4)Ovarian status0.630.7 (0.1--3.6)Previous mastectomy0.940.9 (0.2--4.0)Tumor size0.08^d)^4.3 (0.8--23.7)Metastasis0.09^d)^3.4 (0.8--14.9)Chemotherapy0.14NA^c)^Operative procedure0.09^d)^3.4 (0.8--14.9)Loss of ZO-10.561.5 (0.4--5.7)Loss of E-cadherin0.003^d)^9.0 (1.9--41.7)Gain of vimentin0.08^d)^3.4 (0.8--13.8)Gain of N-cadherin0.831.2 (0.2--6.1)Gain of fibronectin0.202.6 (0.6--11.9)a) OR, odds ratio, b) CI, confidence interval, c) N.A., not available, d) *P*\<0.1. shows the relationship between independent variables including changes in EMT markers and clinicopathological factors and one-year survival. Independent variables which had associations (*P*\<0.1) with one-year survival were then taken forward to multivariate models. Between these variables, the evidence for multicollinearity was absent, because the variance inflation factor for independent variables was less than 4.0 (data not shown). As shown in [Table 6](#tbl_006){ref-type="table"}Table 6.The effect of the expression of epithelial and mesenchymal markers on one-year survivalVariables*P*Adjusted OR^a)^ (95% CI^b)^)Loss of E-cadherin0.02^c)^2.3 (1.3--70.8)Gain of vimentin0.171.4 (0.5--30.8)a) OR, odds ratio, b) CI, confidence interval, c) *P*\<0.05., multiple analysis showed that only loss of E-cadherin was maintained as their independent predictive values (adjusted odds ratio 2.3; *P*=0.02).

DISCUSSION {#s3}
==========

The loss of epithelial markers and gain of mesenchymal markers were observed in some CMGTs tissues in this study. These results indicate that EMT-like phenomenon occurs in canine tissues as with human breast cancer \[[@r6], [@r21]\]. However, these two changes were not always observed simultaneously in the same tissue, rather, weak correlation was observed between the loss of epithelial markers and gain of mesenchymal markers ([Table 4](#tbl_004){ref-type="table"}). These results indicate that the mechanisms of loss of epithelial markers and gain of mesenchymal markers may work independently. In the past study, a CMGT cell line stimulated by transforming growth factor-β acquired vimentin, whereas did not acquire other markers including E-cadherin, β-catenin and N-cadherin \[[@r23]\]. This result also advocated that the expression of each marker is regulated independently.

The loss of ZO-1 and E-cadherin, and the acquisition of vimentin and N-cadherin were observed in much more malignant CMGT tissues as compared with benign tumor tissues ([Table 3](#tbl_003){ref-type="table"}). In human tumors, it is understood that EMT is assumed to be a phenomenon that occurs in accordance with the acquisition of a malignancy, such as cell motility, invasive capacity, apoptotic resistance and drug resistance \[[@r10], [@r22]\]. The changes of markers observed in this study were similar to EMT in human tumors in that the phenomena mainly occur in carcinoma \[[@r8]\]. Therefore, the investigation of various features associated with EMT given above is important to understanding of tumor malignancy and progression in canine tumors.

On the other side, no significant difference of fibronectin between malignant and benign CMGTs tissues was observed. Positive expression of fibronectin was observed in 64.8% of benign tissues and 58.3% of malignant tissues, and no expression in peritumoral normal mammary gland (data not shown). A previous study examined the expression of fibronectin in CMGTs and normal mammary gland \[[@r15]\]. In this study, cytoplasmic staining of fibronectin was observed in epithelial tumor cells in CMGTs, while no staining in normal mammary tissue. Staining characteristics of fibronectin in the present study was in agreement with these findings. Fibronectin may be correlated with tumor genesis rather than acquisition of malignancy.

In the comparison with clinicopathological variables, age was related to loss of ZO-1 (*P*=0.002) and acquisition of vimentin (0.03). The median age of benign and malignant groups was 9.5 (range: 5.3--16) and 11.7 (range: 5.3--11.7), respectively. These markers might have correlated with age, because the sensitivity for malignant tissues of ZO-1 and vimentin was higher than that of benign tissues. In contrast, fibronectin did not show the significant relationship. This might occur, because the specificity of fibronectin for the malignancy was low.

Multivariate analysis for one-year survival indicated that loss of E-cadherin was associated with poor prognosis. This result was in accord with the previous studies which suggested the importance of adhesion factors in metastasis \[[@r2]\] and advocated the hypothesis that the acquisition of mesenchymal feature related to tumor malignancy.

However, this study has some limitations. First, we counted only cells that could be recognized as epithelial tumor cells morphologically, however, the tumor cells undergone complete EMT were thought to change their morphology \[[@r10]\]. Remedies are required to evaluate the EMT in tissue samples precisely. Second, we selected 3 fields across the tumoral area to evaluate the expression of each marker. Because the tumor tissue is heterogeneity, it is debatable issue whether 3 fields are enough or not. Furthermore, several studies suggested that the EMT occurred frequently at invasive front, but less at intra-tumoral. It has been suggested that a local EMT at invasive front takes place owing to exposition to a different microenvironment, such as stromal fibroblast and increase of EMT regulatory transcription factors via stimulations of various cytokines \[[@r1], [@r18]\]. The further investigation including invasive front with enough fields may be necessary to evaluate EMT with more precision.
